Entries by Christian Kähler

Kinase inhibitors: Promising therapeutics for neurodegenerative diseases

Neurodegenerative diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) suffer from a scarcity of effective treatments. Current therapies primarily provide symptomatic relief but do not address the underlying pathology, failing to slow or halt disease progression. This underscores the urgent need to identify new therapeutic targets relevant to the pathology of these conditions. Kinases represent highly tractable drug targets, with kinase inhibitors achieving significant success, particularly in oncology. However, their potential in neurodegenerative diseases remains largely unexplored, presenting a promising avenue for future research and therapeutic development.

BioNsight® cloud: Effortless from data to insights

We are witnessing a significant industrial transformation driven by the adoption of digital tools to manage increasing data volumes and automation to streamline workflows. However, inefficiencies in process development and data management continue to pose major challenges. These challenges are magnified by the complexities of scaling biologics production and ensuring consistency across global teams. Digital tools present an opportunity to improve efficiency and enable remote monitoring of your bioreactor cultures. Introducing BioNsight cloud, a true cloud-based software solution for bioprocess monitoring and analysis. It is fully integrated into the Eppendorf bioprocess control software DASware® control 6 and also features DataHowLab, an innovative AI-enabled analytics solution to save time and resources during process development.

Breakthroughs honoured: 2024 Nobel Prizes

As part of the 2024 Nobel Prize Week, the prestigious awards have been presented. These include the Nobel Prize in Medicine or Physiology for the discoverers of microRNAs as a new class of regulatory molecules, and the Nobel Prize in Chemistry for AI-supported methods in protein design and the rapid calculation of their structures.

CN Bio launches PhysioMimix Bioavailability assay kit: Human 18

CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: Human 18. Harnessing the capabilities of the PhysioMimix Multi-organ System, the kit enhances lead optimization and preclinical testing pipelines, providing an all-in-one solution to generate predictive insights into human oral bioavailability, and better inform lead candidate selection.